Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05191472 · OUTCOME

Overall Response Rate (ORR)

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies · Source last updated 2025-01-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 4 cycles (1 cycle is equal to 21 days)

What was measured

The International Myeloma Working Group (IMWG) uniform response criteria will be used to assess disease response and progression. The response rate is defined as the proportion of patients achieving a partial response (PR), very good partial response (VGPR), complete response (CR), or a stringent complete response (sCR) after 4 cycles of pembrolizumab therapy. A 95% confidence interval will also be reported.

Analysis population: Data not collected

Groups in this outcome

Treatment (Pembrolizumab)

Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Pembrolizumab)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
The International Myeloma Working Group (IMWG) uniform response criteria will be used to assess disease response and progression. The response rate is defined as the proportion of patients achieving a partial response (PR), very good partial response (VGPR), complete response (CR), or a stringent complete response (sCR) after 4 cycles of pembrolizumab therapy. A 95% confidence interval will also be reported.
groups
  1. description
    Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Pembrolizumab)
population Description
Data not collected
reporting Status
POSTED
time Frame
Up to 4 cycles (1 cycle is equal to 21 days)
title
Overall Response Rate (ORR)
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice